BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line BRAF V600E-mutant metastatic colorectal cancer
Kopetz, S., Tabernero, J., & Élez, E. (2025). BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line … Read More
